383 related articles for article (PubMed ID: 32424293)
1. COVID-19 in persons with chronic myeloid leukaemia.
Li W; Wang D; Guo J; Yuan G; Yang Z; Gale RP; You Y; Chen Z; Chen S; Wan C; Zhu X; Chang W; Sheng L; Cheng H; Zhang Y; Li Q; Qin J; ; Meng L; Jiang Q
Leukemia; 2020 Jul; 34(7):1799-1804. PubMed ID: 32424293
[TBL] [Abstract][Full Text] [Related]
2. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Başcı S; Ata N; Altuntaş F; Yiğenoğlu TN; Dal MS; Korkmaz S; Namdaroğlu S; Baştürk A; Hacıbekiroğlu T; Doğu MH; Berber İ; Dal K; Erkurt MA; Turgut B; Çağlayan M; Ayvalı MO; Çelik O; Ülgü MM; Birinci Ş;
J Oncol Pharm Pract; 2020 Oct; 26(7):1676-1682. PubMed ID: 32854573
[TBL] [Abstract][Full Text] [Related]
3. Imatinib for COVID-19: A case report.
Morales-Ortega A; Bernal-Bello D; Llarena-Barroso C; Frutos-Pérez B; Duarte-Millán MÁ; García de Viedma-García V; Farfán-Sedano AI; Canalejo-Castrillero E; Ruiz-Giardín JM; Ruiz-Ruiz J; San Martín-López JV
Clin Immunol; 2020 Sep; 218():108518. PubMed ID: 32599278
[No Abstract] [Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey.
Breccia M; Piciocchi A; De Stefano V; Finazzi G; Iurlo A; Fazi P; Soddu S; Martino B; Palandri F; Siragusa S; Albano F; Passamonti F; Vignetti M; Vannucchi AM
Leukemia; 2020 Oct; 34(10):2813-2814. PubMed ID: 32843716
[No Abstract] [Full Text] [Related]
6. COVID-19 in persons with haematological cancers.
He W; Chen L; Chen L; Yuan G; Fang Y; Chen W; Wu D; Liang B; Lu X; Ma Y; Li L; Wang H; Chen Z; Li Q; Gale RP
Leukemia; 2020 Jun; 34(6):1637-1645. PubMed ID: 32332856
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.
Cheng F; Xiang H; Gale RP; Chen S; Qu J; Guo H; Li Q; Zhang Y; Li W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11025-11030. PubMed ID: 37337067
[TBL] [Abstract][Full Text] [Related]
8. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Baumann T; Delgado J; Montserrat E
Leukemia; 2020 Jul; 34(7):1954-1956. PubMed ID: 32433507
[No Abstract] [Full Text] [Related]
9. What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?
Delgado N; Torres A
Curr Oncol Rep; 2022 May; 24(5):645-650. PubMed ID: 35218499
[TBL] [Abstract][Full Text] [Related]
10. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
12. Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia.
Yu L; Wang H; Gale RP; Qin Y; Lai Y; Shi H; Dou X; Huang X; Jiang Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):449-459. PubMed ID: 33835260
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
Eşkazan AE
Br J Clin Pharmacol; 2020 Sep; 86(9):1790-1792. PubMed ID: 32383276
[No Abstract] [Full Text] [Related]
14. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era.
Qi F; Bao M; Gao H; Zhang X; Zhao S; Wang C; Li W; Jiang Q
Ann Hematol; 2023 Oct; 102(10):2707-2716. PubMed ID: 37578540
[TBL] [Abstract][Full Text] [Related]
15. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
16. Home Treatment of Older People with Symptomatic SARS-CoV-2 Infection (COVID-19): A structured Summary of a Study Protocol for a Multi-Arm Multi-Stage (MAMS) Randomized Trial to Evaluate the Efficacy and Tolerability of Several Experimental Treatments to Reduce the Risk of Hospitalisation or Death in outpatients aged 65 years or older (COVERAGE trial).
Duvignaud A; Lhomme E; Pistone T; Onaisi R; Sitta R; Journot V; Nguyen D; Peiffer-Smadja N; Crémer A; Bouchet S; Darnaud T; Poitrenaud D; Piroth L; Binquet C; Michel JF; Lefèvre B; Lebeaux D; Lebel J; Dupouy J; Roussillon C; Gimbert A; Wittkop L; Thiébaut R; Orne-Gliemann J; Joseph JP; Richert L; Anglaret X; Malvy D;
Trials; 2020 Oct; 21(1):846. PubMed ID: 33050924
[TBL] [Abstract][Full Text] [Related]
17. [Combination of socio-demographic and clinical co-variates for predicting treatment responses and outcomes in patients with chronic myeloid leukemia in the chronic phase].
Zhang XS; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):54-62. PubMed ID: 35231994
[No Abstract] [Full Text] [Related]
18. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2.
Xu X; Yu C; Qu J; Zhang L; Jiang S; Huang D; Chen B; Zhang Z; Guan W; Ling Z; Jiang R; Hu T; Ding Y; Lin L; Gan Q; Luo L; Tang X; Liu J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1275-1280. PubMed ID: 32107577
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyan City, China.
Liu L; Lei X; Xiao X; Yang J; Li J; Ji M; Du W; Tan H; Zhu J; Li B; Jin Z; Liu W; Wu J; Liu Z
Front Cell Infect Microbiol; 2020; 10():284. PubMed ID: 32574282
[TBL] [Abstract][Full Text] [Related]
20. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
